Ketamine and Esketamine for Depression: Evidence and Safety

Evidence checked 2026-09-24 · 8 min read

Updated 24 September 2026. Educational information, not eligibility confirmation, dosing advice or instructions for obtaining or administering ketamine.

Begin by identifying the exact treatment being offered

A service advertising ketamine treatment might mean intravenous ketamine, a compounded oral product or regulated esketamine nasal spray. Those are not interchangeable descriptions. Ask for the medicine’s exact name, formulation, route and prescribing status before comparing outcomes or prices.

A claim that ketamine is approved does not necessarily mean it is approved for depression in the proposed form. The FDA distinguishes ketamine’s anesthetic approval from psychiatric use. A clear provider should explain that distinction without presenting off-label prescribing as either automatically wrong or equivalent to an approved indication.

The current US Spravato indications

US manufacturer information states that Spravato can be used for treatment-resistant depression in adults with or without an oral antidepressant. A separate indication covers depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior, in conjunction with an oral antidepressant.

The official Spravato indication information also states that effectiveness in preventing suicide or reducing suicidal thoughts or behavior has not been demonstrated. Symptom improvement does not remove the need for hospitalization when clinically indicated. These limits are essential when interpreting claims about rapid treatment.

Approvals differ between countries

A US indication should not be copied automatically into an article or care plan for another jurisdiction. The European Medicines Agency’s Spravato information describes use with other antidepressant treatment under its own authorization. Local approval, reimbursement and service eligibility may differ.

Ask the clinic which rules and prescribing information apply where treatment will occur. An international website or an overseas success story does not establish local access. Obtain written confirmation of the actual service rather than assuming a medicine advertised by a group is available at every location.

What treatment-resistant depression means in an assessment

The term usually concerns depression that has not responded sufficiently to adequate treatment trials, but the details need review. A medicine stopped after a few days because of severe nausea is not the same as one taken consistently for an adequate period without benefit.

Bring a treatment history with names, approximate dates, response and reasons for stopping. A specialist should consider the diagnosis, possible bipolar disorder, sleep, physical illness and practical barriers before deciding on the next intervention. Our treatment-resistant depression guide explains this process.

Rapid improvement and durable recovery are different outcomes

Some ketamine-based treatment studies assess symptom changes over short periods. A faster effect can be clinically valuable, but it does not establish that every person will respond or that improvement will last without further care. Ask which outcome a quoted result describes and when it was measured.

Distinguish response, remission and sustained recovery. A percentage from a selected research group should not be presented as your personal probability of success. Request an explanation of how the evidence applies to your diagnosis and treatment history, including the possibility of no meaningful benefit.

Screening is broader than a questionnaire

Assessment should address physical health, blood pressure, other medicines, pregnancy considerations, substance-use history and relevant psychiatric symptoms. Conditions involving blood vessels or previous brain bleeding can be particularly important for esketamine eligibility. The prescriber should use the current product information rather than a generic checklist.

Ask who performs the assessment and who takes responsibility for prescribing. A sales consultation or symptom score is not the same as a medical evaluation. Explain prior dissociation, psychotic experiences or difficult reactions to medicines so that the team can consider appropriate precautions.

Why supervision matters

The official Spravato safety information identifies sedation, dissociation, respiratory depression and misuse risks. In the United States, the restricted REMS program requires treatment in certified settings and monitoring for at least two hours after administration.

Ask what monitoring includes and what happens if you are not ready to leave after the minimum observation period. The presence of a comfortable chair or a remote video connection does not, by itself, establish the capability to respond to an emergency. Staff responsibilities and escalation arrangements should be explicit.

What a treatment visit should explain

Before the visit, the team should provide instructions about preparation, regular medicines and practical arrangements. Follow those instructions rather than improvising a fasting or medication-holding plan from another clinic’s website. Ask whom to contact when a new illness or prescription arises before treatment.

During the appointment, you should know who is present, how to signal distress and what observations are being taken. Consent includes understanding likely experiences and the right to ask questions; it is not just signing a form immediately before receiving a treatment.

Dissociation is an effect, not proof of psychological healing

Dissociation may feel like separation from the body, surroundings or the usual sense of time. It can be unfamiliar or frightening. Experiencing it does not by itself prove that depression has improved, that a memory is accurate or that a particular insight must be followed.

Ask how staff support someone who becomes distressed and how they distinguish expected effects from a concerning reaction. A treatment service should not pressure you to interpret every altered experience as therapeutic progress. Your comfort, consent and later functioning matter alongside symptom measurements.

Plan transport and the rest of the day

Spravato safety information advises against driving or operating machinery until the next day after restful sleep. Arrange transport before treatment and confirm the clinic’s discharge requirements. Do not assume that feeling normal immediately afterward means you can safely drive yourself home.

Consider childcare, work and other responsibilities when planning appointments. A friend collecting you is not automatically agreeing to provide overnight support, so discuss what help is needed. Treatment feasibility includes these arrangements, not only the time spent receiving the medicine.

Compounded ketamine requires a separate discussion

The FDA’s compounding risk alerts include warnings about ketamine products used for psychiatric disorders. Compounded medicines do not undergo the same premarket approval assessment for safety, effectiveness and quality as an FDA-approved product.

Ask why a compounded preparation is proposed, what evidence supports that route and how monitoring will occur. Do not assume a lozenge or a mailed spray is a lower-risk version of a supervised intervention. This article does not provide home-use instructions, dosing conversions or advice on purchasing ketamine.

Discuss substance use and other medication honestly

Tell the clinician about alcohol, sedatives, stimulants and other substances, including occasional use. The information can change the safety assessment and monitoring plan. Fear of being judged should not leave the team unaware of a combination that may affect alertness, breathing or blood pressure.

A history of problematic use deserves individualized assessment rather than a marketing promise that treatment has no misuse risk. Ask how the service monitors emerging problems and who provides support if use becomes difficult to control. See substance use and depression.

Continuation should be planned before the first session

Ask how many initial visits are proposed, when benefit will be reviewed and what happens if there is no improvement. A continuation strategy should address symptoms between sessions, other treatments and access to clinical support. It should not depend solely on repeatedly purchasing another appointment.

Discuss what would lead to reducing, continuing or stopping treatment and how deterioration will be handled. Do not assume that a short initial course guarantees lasting recovery. A written plan helps distinguish a monitored treatment trial from an open-ended package with unclear goals.

Psychotherapy and supportive care are not interchangeable add-ons

A clinic may offer preparation, supportive conversations or psychotherapy alongside medication. Ask which is actually provided, by whom and for what purpose. Calling a session integration does not explain the clinician’s qualifications, the treatment model or the evidence relevant to your situation.

Continue to address daily functioning, relationships, sleep and other needs. A biological intervention does not make those concerns irrelevant. Our treatment-options guide explains how different elements can contribute without treating any single intervention as a complete recovery plan.

Costs and outcome claims need scrutiny

Request a written breakdown covering assessment, medicine, monitoring, follow-up, travel and any proposed maintenance. Confirm insurance or reimbursement arrangements directly. The advertised per-session price may not represent the total commitment, and paying more does not establish superior clinical outcomes.

Ask whether a clinic’s outcome figures include people who stopped early or did not respond, and whether follow-up extends beyond the initial course. Testimonials can describe experiences but cannot establish comparative effectiveness. Avoid services that promise a cure or discourage independent psychiatric advice.

Frequently asked questions

Can Spravato be used without an oral antidepressant?

The US treatment-resistant depression indication permits this, but other indications and jurisdictions differ. Your prescriber must apply the relevant current authorization and assessment.

Does rapid symptom relief prove suicide risk is resolved?

No. Safety requires ongoing assessment, and hospitalization may still be necessary. A medicine is not a replacement for an appropriate crisis plan.

Is a take-home ketamine product equivalent to Spravato?

No. The substance, formulation, route, evidence and monitoring arrangements must be distinguished rather than treated as interchangeable.

Urgent help

If you cannot remain safe, have severe breathing difficulty, collapse or experience another serious reaction, contact emergency services. Do not wait for a ketamine consultation or the next planned session. Our crisis-support page provides additional signposting.